Doxorubicin and ifosfamide-mesna in advanced and recurrent uterine sarcomas

Purpose of investigation: To report the experience of a single institution in the south of Israel with doxorubicin and ifosfamide-mesna in patients with advanced/recurrent uterine sarcomas.

Methods: The hospital records of five patients with advanced/recurrent uterine sarcomas who had combination chemotherapy with doxorubicin and ifosfamide-mesna were retrospectively reviewed. Doxorubicin 30 mg/m2 was given on days 1 and 2 and ifosfamide 2000 mg/m2 (+ mesna, W/W 60%) was given on days 1, 2 and 3 of every 21 days. Dose intensity, relative dose intensity and average relative dose intensity (ARDI) of chemotherapy were calculated. Response was determined using clinical evaluation and radiological reports. Toxicity was graded using the National Cancer Institute (NCI) criteria.

Results: The median ARDI of the combination of doxorubicin and ifosfamide received by the patients was 0.68 (range, 0.53-0.74). One (20%) patient had disease complete response lasting three months and four (80%) patients had progressive disease. Toxicity was mainly hematological with grade 3 or 4 leukopenia--four (80%) patients, neutropenia--four (80%), thrombocytopenia--one (20%) and anemia--one (20%). Non-hematological toxicity was negligible. At follow-up, four (80%) patients had died of disease and one (20%) was alive with disease.

Conclusion: Although the combination of doxorubicin and ifosfamide has certain activity in advanced/recurrent uterine sarcomas, the toxicity is of much concern and the results of treatment in terms of response duration and survival are poor.

Uterine sarcoma; Chemotherapy; Doxorubicin; Ifosfamide; Disease response; Toxicity

[1] Mansi J.L., Fisher C., Wiltshaw E., MacMillan S., King M., Stuart-Harris R.: "A phase 1-11 study of ifosfamide in combination with adriamycin in the treatment of adult soft tissue sarcoma". Eur. J. Cancer Clin. Oncol., 1988, 24, 1439.

[2] Schutte J., Kellner R., Seeber S.: "Ifosfamide in the treatment of soft-tissue· sarcomas: experience at the West German Tumor Center, Essen". Cancer Chemother. Pharmacol., 1993, 31, S194.

[3] Schutte J., Mouridsen H.T., Stewart W., Santoro A., van Oosterom A.T., Somers R. et al.: "Ifosfamide plus doxorubicin in previously untreated patients with advanced soft tissue sarcoma". Eur. J. Cancer, 1990, 26, 558.

[4] Loehrer P.J. Sr., Sledge G.W. Jr., Nicaise C., Usakewicz J., Hainsworth J.D., Martelo O.J. et al.: "Ifosfamide plus doxorubicin in metastatic adult sarcomas. A multi-institutional phase II trial". J. Clin. Oncol., 1989, 7, 1655.

[5] Weh H.J., Zugel M., Wingberg D., Schwarz R., Zornig C., Dietel M., Hossfeld D.K.: "Chemotherapy of metastatic soft tissue sarcoma with a combination of adriamycin and DTIC or Adriamycin and ifosfamide". Onkologie, 1990, 13, 448.

[6] Steward W.P., Verweij J., Somers R., Spooner D., Kerbrat P., Clavel M. et al:: "Granulocyte-macrophage colony-stimulating factor allows safe escalation of dose-intensity of chemotherapy in metastatic adult soft tissue sarcomas: a study of the European Organization for Research and Treatment of Cancer, Soft Tissue and Bone Sarcoma Group". J. Clin. Oneal., 1993, 11, 15.

[7] Edmonson J.H., Ryan L.M., Blum R.H., Brooks J.S., Shiraki M., Frytak S., Parkinson D.R.: "Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas". J. Clin. Oneal., 1993, 11, 1269.

[8] Barista I., Tekuzman G., Yalcin S., Gullu I., Guler N., OzisikY. et al.: "Treatment of advanced soft tissue sarcomas with ifosfamide and doxorubicin combination chemotherapy". J. Surg. Oneal., 2000, 73, 12.

[9] Myers C.E., Chabner B.A.: "Anthracyclines". In: Chabner B.A., Collins J.M. (eds.), Cancer Chemotherapy: Principles and Practice, Philadelphia, J.B. Lippincott Company, 1990, 356.

[10] Colvin M., Chabner B.A.: "Alkylating agents". In: Chabner BA., Collins J.M. (eds.), Cancer Chemotherapy: Principles and Practice, Philadelphia, J.B. Lippincott Company, 1990, 276.

[11] Piura B., Rabinovich A., Yanai-Inbar I., Cohen Y., Glezeman M.: "Uterine sarcoma in the south of Israel: study of 36 cases". J. Surg. Oneal., 1997, 64, 55.

[12] Levin L., Hryniuk W.M.: "Dose intensity analysis of chemotherapy regimens in ovarian carcinoma". J. Clin. Oneal., 1987, 5, 756.

[13] Levin L., Hryniuk W.M.: "The application of dose intensity to problems in chemotherapy of ovarian and endometrial cancer". Semin. Oneal., 1987, 14 (suppl. 4), 12.

[14] Common Terminology Criteria for Adverse Events, Version 3.0, Revised June 10, 2003, National Cancer Institute, http://ctep.cancer.gov/forms/CTCAEv3.pdf

[15] Omura G.A., Major F.J., Blessing J.A., Sedlacek T.V., Thigpen J.T., Creasman W.T., Zaino R.T.: "A randomized study of adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas". Cancer, 1983, 52, 626.

[16] Sutton G.P., Blessing J.A., Rosenshein N., Photopulos G., DiSaia P.J.: "Phase II trial of ifosfamide and mesna in mixed mesodermal tumors of the uterus (A Gynecologic Oncology Group study)". Am. J. Obstet. Gynecol., 1989, 161, 309.

[17] Hawkins R.E., Wiltshaw E., Mansi J.L.: "Ifosfamide with or without adriamycin in advanced uterine leiomyosarcoma". Cancer Chemother. Pharmacol., 1990, 26, S26.

[18] Sutton G.P., Blessing J.A., Barrett R.J., McGehee R.: "Phase II trial of ifosfamide and mesna in leiomyosarcoma of the uterus: a Gynecololgic Oncology Group study". Am. J. Obstet. Gynecol., 1992, 166, 556.

[19] Sutton G., Blessing J.A., Park R., DiSaia P.J., Rosenshein N.: "Ifosfamide treatment of recurrent or metastatic endometrial stromal sarcomas previously unexposed to chemotherapy: a study of the Gynecologic Oncology Group". Obstet. Gynecol., 1996, 87, 747.

[20] Sutton G., Blessing J.A., Malfetano J.H.: "Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcomas of the uterus: A Gynecologic Oncology Group Study". Gynecol. Oneal., 1996, 62, 226.

[21] Sutton G., Brunetto V.L., Kilgore L., Soper J.T., McGehee R., Olt G., et al.: "A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: A Gynecologic Oncology Group study". Gynecol. Oneal., 2000, 79, 147.